Plasma BDNF levels, BDNF Val66Met polymorphism, and their association with phenoconversion in isolated REM sleep behavior disorder
European Neurology · 2026
DOI: 10.1159/000550711 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Neurology, 2026. Verfasst von Yajie Zang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Brain-Derived Neurotrophic Factor, REM Sleep Behavior Disorder. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Brain-derived neurotrophic factor (BDNF) plays an important role in the survival of dopaminergic neurons. Clinical studies have suggested that serum BDNF levels are reduced in patients with Parkinson’s disease (PD). However, no study has investigated peripheral BDNF levels and BDNF Val66Met polymorphism in the prodromal stage of PD and their relationship with disease conversion.
Methods
120 patients with video-polysomnographically (v-PSG) confirmed iRBD and 120 healthy controls (HCs) were enrolled. Genetic analyses were performed, and plasma levels of BDNF were measured. All patients with iRBD underwent comprehensive clinical testings, and 107 iRBD patients were prospectively followed-up.
Results
Plasma BDNF levels were significantly lower in the iRBD group than in HCs (18878.85 pg/ml vs. 24649.85 pg/ml, p = 0.002), but no differences were observed in BDNF Val66Met carrier rates between the two groups. Plasma BDNF levels did not differ significantly between BDNF Val66Met carriers and non-carriers. Notably, higher plasma BDNF levels were associated with an increased risk of short-term disease con-version (Hazard Ratio = 3.418, 95% CI 1.520-7.684, p = 0.003), whereas BDNF Val66Met carrier rates showed no such association.
Conclusion
Our findings suggest that plasma BDNF is significantly associated with iRBD and may likely serve as a prognostic biomarker for the development of neurodegenerative dis-ease. However, the BDNF Val66Met polymorphism may not be involved in the path-ogenesis of iRBD as well as phenoconversion in the studied population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
- Department of Biobank, Xuanwu Hospital of Capital Medical University, Beijing, China.
- National Clinical Research Center for Geriatric Disorders, Xuanwu Hospital of Capital Medical University, Beijing, China.
- School of Health Professions, Stony Brook University, New York, New York, USA.
- Department of Biobank, Xuanwu Hospital of Capital Medical University, Beijing, China, yanningcaimailbox@163.com.
- National Clinical Research Center for Geriatric Disorders, Xuanwu Hospital of Capital Medical University, Beijing, China, yanningcaimailbox@163.com.
Zitieren
APA
Zang, Y., Zhang, H., Ruan, Z., Wang, T., Li, Y., Yuan, Y., Yu, Q., Cai, Y., & Mao, W. (2026). Plasma BDNF levels, BDNF Val66Met polymorphism, and their association with phenoconversion in isolated REM sleep behavior disorder. European Neurology. https://doi.org/10.1159/000550711
Vancouver
Zang Y, Zhang H, Ruan Z, Wang T, Li Y, Yuan Y, et al. Plasma BDNF levels, BDNF Val66Met polymorphism, and their association with phenoconversion in isolated REM sleep behavior disorder. European Neurology. 2026. doi:10.1159/000550711
BibTeX
@article{Zang2026,
author = {Zang, Yajie and Zhang, Hui and Ruan, Zheng and Wang, Ting and Li, Yuan and Yuan, Yuan and Yu, Qian and Cai, Yanning and Mao, Wei},
title = {Plasma BDNF levels, BDNF Val66Met polymorphism, and their association with phenoconversion in isolated REM sleep behavior disorder},
journal = {European Neurology},
year = {2026},
doi = {10.1159/000550711}
}
EUVIMED